HC Wainwright Analysts Lift Earnings Estimates for PRAX

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Praxis Precision Medicines to ($3.78), up from a previous estimate of ($4.28).
• Prax's stock currently holds a consensus rating of “Moderate Buy”, with an average price target of $95.22 from various analysts.
• The company's latest quarterly earnings report showed a loss of ($3.31) EPS, which beat analysts' expectations of ($3.40) EPS.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Analysts at HC Wainwright upped their Q3 2025 EPS estimates for Praxis Precision Medicines in a research report issued to clients and investors on Tuesday, August 5th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($3.78) for the quarter, up from their prior forecast of ($4.28). HC Wainwright has a "Buy" rating and a $115.00 price objective on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines' Q4 2025 earnings at ($4.25) EPS, FY2025 earnings at ($14.63) EPS, Q1 2026 earnings at ($4.23) EPS, Q2 2026 earnings at ($4.50) EPS, Q3 2026 earnings at ($4.60) EPS, Q4 2026 earnings at ($4.64) EPS, FY2026 earnings at ($17.98) EPS, FY2027 earnings at ($15.86) EPS and FY2028 earnings at ($7.64) EPS.

PRAX has been the subject of several other reports. Chardan Capital restated a "buy" rating and set a $80.00 target price on shares of Praxis Precision Medicines in a report on Tuesday, July 29th. Oppenheimer increased their price objective on Praxis Precision Medicines from $97.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Wedbush raised their target price on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an "underperform" rating in a report on Monday, May 5th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $80.00 price target on shares of Praxis Precision Medicines in a report on Thursday, June 12th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $95.22.

Praxis Precision Medicines Stock Down 2.8%

Shares of PRAX traded down $1.33 during trading hours on Thursday, hitting $45.94. The company had a trading volume of 438,540 shares, compared to its average volume of 543,862. Praxis Precision Medicines has a 52-week low of $26.70 and a 52-week high of $91.83. The stock's 50 day moving average price is $48.11 and its 200 day moving average price is $48.27. The firm has a market cap of $967.04 million, a P/E ratio of -3.74 and a beta of 2.62.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($3.31) earnings per share for the quarter, topping the consensus estimate of ($3.40) by $0.09. Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 60.07%.

Hedge Funds Weigh In On Praxis Precision Medicines

Several hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its holdings in Praxis Precision Medicines by 88.3% in the second quarter. Nisa Investment Advisors LLC now owns 629 shares of the company's stock valued at $26,000 after acquiring an additional 295 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Praxis Precision Medicines in the 4th quarter worth $30,000. CWM LLC boosted its stake in shares of Praxis Precision Medicines by 877.9% during the 2nd quarter. CWM LLC now owns 753 shares of the company's stock valued at $32,000 after purchasing an additional 676 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Praxis Precision Medicines by 6,075.4% during the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock valued at $152,000 after purchasing an additional 3,949 shares in the last quarter. Finally, Graham Capital Management L.P. purchased a new position in shares of Praxis Precision Medicines during the fourth quarter valued at about $209,000. 67.84% of the stock is owned by hedge funds and other institutional investors.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.